Bio-Rad Laboratories, Inc.Class A (BIO) — Analysis Summary
Bio-Rad Laboratories, Inc.Class A (BIO) has a market cap of $10.43B with year-over-year revenue growth of +0.7%. Net margin stands at 29.4%. The stock trades at a P/E ratio of 46.9.
Key Takeaways
- Revenue changed +0.7% year-over-year
- Net margin of 29.4%
- P/E ratio of 46.9
Compared to other companies in the LABORATORY ANALYTICAL INSTRUMENTS sector, BIO posted revenue growth of +0.7% and trades at a P/E of 46.9.
Bio-Rad Laboratories, Inc.Class A (BIO)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at 1.1x — minimal debt service cushion
Net income fell 70.7% vs the prior period.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Employees
7,450
Headquarters
HERCULES, CA
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.